New Opportunities for Antineoplastic Drugs

Medicilon has been recognized as one of the top drug discovery contract research organizations (CRO) in China and is managed by a team of scientists with a wealth of experience in US-based pharmaceutical and biotechnology companies. As our areas of expertise and service capabilities continue to expand, more and more pharmaceutical and biotechnology companies have taken advantage of our integrated drug discovery and development services. Email:marketing@medicilon.com.cn Web:www.medicilon.com

In recent years, the incidence of malignant tumors increased year by year, anti-tumor drugs has become the fastest growing market areas. There are increased nearly 4 million new cancer patients annual in China, and overall size of anti-tumor drug market has reached nearly 100 billion Yuan, but it is far from meeting the actual needs.

Mostly prices of Antineoplastic drugs are high, not only bring a heavy burden to the family of patients to, but also test the wisdom of pricing for the enterprise. Before the negotiation system, many of the new marketed antineoplastic drugs were expensive, many families and patients had to retreat, or take conservative Chinese medicine treatment, or at risk of purchasing foreign drugs or APIs.

It should be said that China's anti-tumor drug market development is lagging behind and deformed. A large number of cancer-assisted drugs, proprietary Chinese medicine wasted health insurance resources, those who really have the exact effect of drugs, many patients cannot afford due to tender, or because of health insurance adjustment lag and other reasons.

With the development of genetic testing technology, precision medicine has arrived. In the field of anti-tumor, gene-based targeting drugs have become first-line antitumor drugs because of its significant effect and minimal side effect.

Therefore, tumor gene is complex, the existing drug coverage target is not enough, blindly follow the trend, imitation of many enterprises, which all have become the potential factors to restrict the development of targeted drugs. Data show that the treatment of lung cancer gefitinib, for example, CFDA in the approval of the business as many as 40, erlotinib is up to more than 100.

Targeting drugs must be one of the main anti-tumor drugs in the future, like the field of antibiotics as a full range, for different targets have different drugs, but one should be noticed: do not repeat and imitate.

Whether anti-cancer drugs can enter health insurance is not only related to the health of millions of patients, but also related to the success or failure of a product. In the past, China's health insurance system is lagging behind; many cutting-edge, new listing of drugs cannot be included in the health insurance directory, which is also because of backward enterprise education. Enterprises will generally start listing large-scale education to promote after drugs listed. Many clinical experts and medical workers also need some time to understand on the use of drugs, so health care will be more delayed.

Some domestic enterprises should fully study the foreign advanced experience. Some foreign cancer drug production enterprises will be published from time to time to progress, and let doctors and patients look forward to their projects. Once the clinical trial is successful, this projects can be quickly accepted by clinical and patients. Even if there is the possibility of failure, the enterprises establishing a corporate image of responsibility, and is also very favorable for follow-up branding building.

In addition to the government financial health insurance, enterprises should also actively try to build cooperation projects with commercial insurance. Now a lot of insurance companies specifically launched for the insurance products of malignant tumors, the combination of pharmaceutical companies and insurance companies should also be a positive exploration of one of the direction.